Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001044982 | SCV001208809 | pathogenic | Hereditary hemorrhagic telangiectasia | 2020-07-25 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in ENG are known to be pathogenic (PMID: 15879500, 20656886, 22385575). This variant has been observed in an individual affected with hereditary haemorrhagic telangiectasia (PMID: 20414677). ClinVar contains an entry for this variant (Variation ID: 842548). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Asp491Alafs*26) in the ENG gene. It is expected to result in an absent or disrupted protein product. |
NIHR Bioresource Rare Diseases, |
RCV001263071 | SCV001441148 | pathogenic | Telangiectasia, hereditary hemorrhagic, type 1 | 2018-01-01 | criteria provided, single submitter | research | PVS1+PM2+PP4 |
Ambry Genetics | RCV002393222 | SCV002697523 | pathogenic | Cardiovascular phenotype | 2018-03-05 | criteria provided, single submitter | clinical testing | The c.1472_1475delACAG pathogenic mutation, located in coding exon 12 of the ENG gene, results from a deletion of 4 nucleotides at nucleotide positions 1472 to 1475, causing a translational frameshift with a predicted alternate stop codon (p.D491Afs*26). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Fulgent Genetics, |
RCV001263071 | SCV002802315 | likely pathogenic | Telangiectasia, hereditary hemorrhagic, type 1 | 2021-10-19 | criteria provided, single submitter | clinical testing |